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Cancerous diseases present a formidable health problem worldwide. While the chemotherapy of cancer, in conjunction with other
treatment modalities, has reached a signiﬁcant level of maturity, eﬃcacious use of such agents is still restricted by numerous phar-
macologicaldeﬁciencies,suchaspoorwatersolubility,shortserumcirculationlifetimes,andlowbioavailabilityresultingfromlack
of aﬃnity to cancer tissue and inadequate mechanisms of cell entry. More critically still, most drugs suﬀer from toxic side eﬀects
and a risk of drug resistance. The class of platinum anticancer drugs, although outstandingly potent, is particularly notorious in
that respect. Among the countless methods developed in recent years in an eﬀort to overcome these deﬁciencies, the technology of
polymer-drug conjugation stands out as a particularly advanced treatment modality. The strategy involves the bioreversible bind-
ing, conjugating, of a medicinal agent to a water-soluble macromolecular carrier. Following pharmacokinetic pathways distinctly
diﬀerent from those of the common, nonpolymeric drugs, the conjugate so obtained will act as a prodrug providing safe transport
of the bioactive agent to and into the aﬀected, that is, cancerous cell for its ultimate cell-killing activity. The present treatise will
acquaint us with the pharmacological fundamentals of this drug delivery approach, applied here speciﬁcally to the metalorganic
platinum-typedrugsystemsandtheorganometallicferrocenedrugmodel.Wewillseejusthowthistechnologyleadstoconjugates
distinctly superior in antiproliferative activity to cisplatin, a clinically used antitumor agent used here as a standard. Polymer-drug
conjugation involving metal-based and other medicinal agents has unquestionably matured to a practical tool to the pharmaceu-
tical scientist, and all indications point to an illustrious career for this nascent drug delivery approach in the ﬁght against cancer
and other human maladies.
Copyright © 2008 Eberhard W. Neuse. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
The delivery of medicinal agents to the human body for
healing purposes is probably as old as mankind. While in
the early days such agents, now generally known as drugs,
were simply delivered from hand to mouth, perhaps also by
rubbing into the skin, or placing on an open wound, we
are using more numerous and doubtlessly more complicated
modalities of delivery in modern times, simply prompted
by the need to control and combat a hugely increased va-
riety of identiﬁed inﬁrmities. A new stage of chemothera-
peutic development was attained, more than a quarter of a
century ago, with the advent of the polymer-drug conjuga-
tion paradigm, which teaches the use of polymeric, that is,
macromolecularcompoundsaspivotalhelpersindrugdeliv-
ery. Numerous delivery techniques, taking advantage of the
functional assistance provided by a macromolecular partner,
have since been successfully developed for various routes of
administration, not only the time-proven oral route (“just
swallow it!”), but more importantly the parenteral routes in-
volvingintravenous,intraperitoneal,orintramuscularmeth-
ods. It is particularly these parenteral administration tech-
niques that have led to the successful use of partaking poly-
mers. We will learn more about those developments further
down the road in this paper. Although metal-free drug sys-
tems will ﬁnd due mentioning in this treatise, emphasis will
be on metal-containing compounds in accordance with this
journal’s mission. Before we delve into this core topic, we are
prudently advised to take a primer lesson on the pharma-
cokineticpathwaysgenerallyavailabletoadrug—anydrug—
after its administration to the mammalian organism, espe-
cially the human body. Section 2 will guide us leisurely on
this learning path.2 Metal-Based Drugs
2. WHAT WE SHOULD KNOW ABOUT DRUG
ADMINISTRATION
2.1. Thecancerproblem
Malignancies and cardiac diseases together provide the main
cause of death in the developed world. In the United States,
oneinev erythr eepersonscurr entlyali v eisestimat edt oc on-
tract some form of cancer, and every ﬁfth person will ulti-
mately succumb to it. A similar pattern of mortality obtains
in other Western nations, and an even gloomier prognosis
is observed in many developing countries. In South Africa,
for example, cancer is the second-most common cause of
death in the white, colored, and Asian population, and the
third-most common cause in the black population group.
Despite major variations among the diﬀerent racial groups
and incomplete registries especially in the black group, sta-
tistical data leave no doubt that, on average, South African
rates for certain malignancies such as cervical, oesophageal,
and skin cancers rank among the highest worldwide. Can-
cers of the lung and prostate rate among the top six cancers
with white and nonwhite males, breast and cervical cancers
are among the top six with white and nonwhite females, and
melanoma represents one of the top six cancers with white
females. Other types of cancer, including the various forms
of leukaemia, although of lower incidence, are nonetheless
causative for serious concern. The problem will be aggra-
vated in the coming years as increasing urbanization is ex-
pected to create environmental and dietary conditions con-
ducive to further initiation and spread of cancers; it will be
further compounded by the ﬁnding that cancerous aﬄic-
tions occur in approximately one third of all male and fe-
male adult breadwinners in the age bracket of 15–54 years.
A novel factor now coming into play is the rapid spread of
AIDS;immunodepressedpatientswillbeatspecialrisktode-
velop early cancerous lesions, and virus-related cancers may
well ﬁnd particularly suitable targets among such patients.
Chemotherapy constitutes an important cancer treat-
ment modality, alone or in conjunction with other treat-
ment regimens. However, despite much progress in drug re-
search, results on average have been highly discouraging. Let
uspauseforamomentandexaminethisunsatisfactorystate-
of-aﬀairs more closely.
Presently used anticancer drugs suﬀer from a multitude
of severe pharmacological deﬁciencies, all of which continue
to contribute to the limitations of eﬀectiveness generally ex-
perienced in current clinical practice. Typical pharmacolog-
ical shortcomings include the following: (i) lack of cell speci-
ﬁcity, with ensuing drug distribution into both normal and
transformed cells, that is, in consequence, drug application
will be excessively wasteful; (ii) inadequate water solubility,
hampering swift, and eﬃcacious drug distribution in the
body’s aqueous ﬂuid system, with resulting enhanced ex-
posure to macrophage activity; (iii) decreased serum half-
life as a consequence of catabolism, protein binding by the
reticuloendothelial system, or eﬃcacious excretion mech-
anisms; (iv) monophasic salt-like or charged structure, in-
hibiting membrane penetration and cell entry through nor-
mal passive diﬀusion, and resulting from these deﬁciencies,
only a small fraction of the medicinal agent will successfully
enter intracellular space for interaction with nuclear DNA
or proteinaceous constituents; (v) excessive systemic toxic-
ity, which grossly diminishes therapeutic drug eﬃcacy; and
(vi) lack of long-term eﬃcaciousness because of inherent
or induced drug resistance. Both (v) and (vi) are clearly the
most aggravating factors added to abovementioned deﬁcien-
cies, they generally necessitate premature discontinuation of
drug-speciﬁc therapy, and thus, tend to reactivate tumorous
or metastatic growth. As an overall consequence of the cited
drugdeﬁciencies,periodsofregressiontendtobelimited,re-
lapses occur frequently, and complete cures of most types of
cancer by chemotherapy alone are still the exception rather
than the rule.
A rather discomforting outlook indeed! Why then bring
up this gloomy topic? Will you, the thoroughly depressed
reader, not be prompted to disembark speedily from the
wrongferryboatandrunforgreenerpastureselsewhere?The
answer: worldwide eﬀorts in biomedical research are striving
to overcome existing chemotherapeutic hurdles through the
expediency of developing eﬃcacious cancer-ﬁghting tools,
and it is precisely this global development drive in which
macromolecular compounds are crucial participants and
ﬁnd their true and foremost destiny. In Section 2.2 we will
explore the background to this unique role played by poly-
mers and their outstanding capabilities as delivery vehicles
in the chemotherapeutic treatment of cancerous diseases.
2.2. Thepolymer-drugconjugationconcept
To begin with, using text book knowledge, we will examine
a typical medicinal agent’s pharmacokinetic fate as it unfolds
upon the drug’s administration by the common intravenous,
intramuscular, or oral techniques. For these, Figure 1 depicts
exemplifying curves, given in terms of the agent’s serum con-
centration as a function of postadministration time. In typi-
cal fashion, the intravenous route (curve A) delivers highest
initialconcentrations,whichdecreasemoreorlessasymptot-
ically with time, ultimately to reach zero-concentration level.
Intramuscular administration (curve B) needs time for the
curv etoascendfr omzer otoamaximum,afterwhichitgrad-
ually descends to zero. The oral route (curve C), while like-
wise providing a concentration maximum (generally below
that of curve B), requires time extension for that trend, if
one considers the long and obstacle-cluttered gastrointesti-
nal pathway the drug has to follow before entering the blood
pool.
Atthispoint,welearnthatforanyadministereddrugsys-
tem there are two critical serum concentration limits, repre-
sented by the dashed lines in Figure 2: a lower limit below
which the drug has ceased to produce any therapeutic eﬀect,
andanupperlimitabovewhichthedrugexertsvariousforms
of toxicity in the organism. For a drug employed via intra-
venous injection, which is the administration mode favored
for polymer-drug conjugates, curve A allows for drug appli-
cationdevoidoftoxicsideeﬀects,yetprovidinglimitedeﬀec-
tiveness time. In contrast, curve B, representing an increased
initial dosis, yields a considerably extended eﬀectiveness pe-
riod; this, however, does happen at the cost of emergingEberhard W. Neuse 3
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Figure 1: Drug serum concentration versus time for three admin-
istration routes.
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Figure 2: Drug serum concentration versus time for two diﬀerent
doses.
toxicity. Hence, for a medicinal agent to remain therapeu-
tically eﬃcacious without toxic eﬀects, its serum concentra-
tion must stay between the dotted lines over an optimally ex-
tended time span as schematically depicted by curve C.
An obvious approach toward achieving this goal of con-
tinuous, nontoxic bioactivity, although being tedious and
cumbersome, would involve repetitive drug administration
within carefully identiﬁed time intervals and with doses ad-
justed so as to maintain serum concentrations just below
toxiclevels.Betterstill,onemightdesignadrugdeliverycon-
struct that would, upon a single bolus administration, al-
low for a slow and gradual intraserum release of the agent
from some sort of depot system. An optimally eﬃcacious
concentration trend for this model is schematically shown in
Figure 3.
Needless to say, the pharmaceutical community, far from
being asleep, has over the past two decades focused research
c
Toxic level
Min. eﬀective level
c = d r u gc o n c e n t r a t i o ni np l a s m a
Segment between vertical dotted lines represents
eﬀectiveness time
Figure 3: Drug serum concentration versus time for slow-release
modality.
activitiesonamassivescalepreferentiallyonthiskindofdrug
delivery system, generally with highly promising outcomes.
Thus, microencapsulated drugs in the form of microspheres,
nanospheres, and liposomes have been developed and suc-
cessfully tested, and so have numerous implantable matrices
capable of liberating embedded drugs into the body’s ﬂuid
system and other body compartments through bioleaching,
bioerosion, or simply through matrix biodegradation. These
amply discussed drug delivery systems [1–3], all aiming at
enhanced therapeutic eﬀectiveness of medicinal agents and
by-and-large quite eﬃcacious in their own right, fall outside
the deﬁnition of the narrow term of polymerdrug conjuga-
tion and, hence, outside the scope of the present text.
Deviatinginitsmodusoperandifromtheaforementioned
drug delivery constructs, the drug conjugation modality em-
bodies a symbiotic union between two equally contributing
partners: the polymer acts as a carrier and transport vehi-
cle (it “knows” how to overcome biological hurdles and de-
liverthedrugloadsafelyatthedesignatedterminal),whereas
its “partner in healing”, the drug proper, enjoys the safe ride
and exerts its bioactivity in the target tissue. The notion of
pairing up a bioactive agent with a transporter vehicle, born
in the early 1970s, was forcefully advanced by Ringsdorf [4],
whodeﬁnedandreﬁnedthisparadigminpalpabletermsand
set in motion broad-based development activities in numer-
ous laboratories, on the strength of which the notion has by
now matured to a highly sophisticated pharmaceutical tool.
It utilizes the advantageous pharmacokinetic behavior of
polymeric compounds in the mammalian body, paired with
their enormous compositional versatility allowing for near-
limitless structural modiﬁcations of these large molecules.
In practical terms, the technique comprises the bioreversible
binding (conjugation) of a bioactive agent, typically an an-
titumor drug, to a water-soluble macromolecular carrier
molecule designed and synthesized in strict conformance
withpharmaceuticalguidelines.Speciﬁcally,thecarrierpoly-
mer will be composed of the following: (i) subunits contain-
ing some molecular entity permitting facilitated cell entry;
(ii) other subunits equipped with intra- or extrachain water-
solubilizing groups; (iii) still other units featuring a hom-
ing device capable of directing the polymer-drug assembly,4 Metal-Based Drugs
the conjugate, selectively to the target tissue; and (iv), most
importantly, units equipped with functional groups suitable
for the critical conjugation step involving bioreversible drug
binding to the polymer. The conjugate represents a prodrug,
fromwhichtheactiveagentishydrolyticallyorenzymatically
released into the predestined biological environment, which,
for anticancer action, are the cytoplasmic lysosomes and cell
nuclei. A conjugate conforming in structure to those speciﬁ-
cations will demonstrate therapeutic superiority on account
of the following factors.
(i) Even if insoluble in water, the medium providing the
circulating blood pool and other ﬂuids, the intrave-
neously (IV) or intraperitoneally (IP) administered
polymer-anchored drug, now perfectly water-soluble,
willbeswiftlycarriedintocentralcirculationorthein-
traperitoneum. This will ensure eﬃcient distribution
of the bound drug in the ﬂuid system, a requirement
most vital for drug transport within the body.
(ii) While in transit in the central circulation system, the
polymer-bound drug, notably if additionally modiﬁed
byinclusionofoligo(ethyleneoxide)units,willexperi-
ence temporary protection from serum protein bind-
ing, enzymatic attack, and other scavenging processes.
As a result, renal clearance (i.e., excretion through the
kidneys’ globular system) will be minimized, while
serum life-time and drug bioavailability will be ex-
tended as part of a major change in biodistribution.
(iii) The dreaded toxic side eﬀects invariably caused by the
common,nonpolymeric medicinalagentswillbemin-
imized through carrier attachment, as now the “an-
chored” agent will be constrained in body and organ
distribution while in transit.
(iv) The connecting groups incorporated into the
polymer-drug linker for ultimate drug release can
be uniquely designed so as to remain intact while
the conjugate is on its way to target in the body’s
ever so slightly basic (ph∼7.5) environment, yet to
undergo bioﬁssion once the carrier-drug assembly has
reached intracellular (speciﬁcally lysosomal) space.
Such bioﬁssion may be mediated by the lysosomal
proteolytic enzymes, or else may simply follow a
hydrolytic pathway, taking advantage of the acidic
(ph∼5) intralysosomal environment. Reduced to
monomeric size, the agent so liberated will now be
able to undergo extravasation through penetration
of the lysosomal membrane (a transport step not
generally available to a macromolecular compound)
and head for its ultimate destination, which for most
anticancer drugs is the cell’s nuclear DNA.
(v) The presence of a “homing” (i.e., actively targeting)
group will lead to enhanced drug aﬃnity for the trans-
formed, that is,cancerous cell, thus facilitating guided
drug transport. To exemplify this process, we wish
to take a look at a cancer-targeting system featur-
ing galactosamine as the homing device. This carbo-
hydrate shows aﬃnity for the asialoglycoprotein re-
ceptor in hepatocytes and thus, if attached to a cy-
totoxic agent, directs the latter eﬃciently to liver tis-
sue, thereby providing cell-killing action against hep-
atomas, a form of liver malignancies. Other success-
fully used homing groups are represented by cationic
moieties, tracking the conjugate preferentially to neo-
plastic tissue as a consequence of electrostatic attrac-
tion to the negative surface charge displayed by many
cancer cells. Still other homing systems utilize the
aﬃnity of monoclonal antibodies for speciﬁc cancer-
associatedantigens.Thisresearcharea,whilestillham-
pered by pharmacological problems of solid-state in-
solubility, immunogenicity, and in-transit vulnerabil-
ity to side reactions and degradation, has proved emi-
nently promising, and considerable progress has been
achieved in recent years.
(vi) Thepolymer-drugconjugatewillexperiencefacilitated
endocytotic cell entry, thus circumventing potential
problems caused by drug polarity or ionicity in the
normal process of membrane crossing by passive dif-
fusion common to nonpolymeric solutes. The mech-
anism is pinocytotic in nature and thus not subject
to the limitations imposed by the reticuloendothe-
lial system on phagocytotically captured particulates.
Ideally, adsorptive pinocytosis is utilized by the con-
jugate for increased eﬃciency of translocation, and
cationicpolymersaregoodexamplesofcompoundsso
translocated. In cases where excessive P-glycoprotein-
mediated drug eﬄux from endocytic space and conse-
quentresistanceproblemshavedeveloped, thepinocy-
totic cell entry mechanism, through replenishment of
the intracellular drug pool, assumes unique impor-
tance as a means of counteracting the dreaded phe-
nomenon of drug resistance and restoring chemother-
apeutic drug activity.
(vii) Polymerconjugates,in commonwithmacromolecules
in general, tend to accumulate in solid tumors be-
cause of enhanced intratumoral vascular permeabil-
ity, allowing for substantial leakage of the polymeric
molecules into the tumor tissue. Whereas, in normal
tissues, macromolecules in interstitial space are ef-
ﬁciently recovered and eliminated by the lymphatic
system, such lymphatic clearance is grossly retarded
in tumorous tissue and so represents a weighty fac-
tor contributing to the tumoritropic characteristics of
macromolecular compounds. This enhanced perme-
ability and retention (EPR) eﬀect associated with poly-
mers provides passive targeting and renders polymer-
drug conjugate administration more eﬃcacious while
reducing systemic toxicity in other organs.
(viii) Through the expediency of introducing bioﬁssionable
segments into the backbone, a polymer can be ren-
deredbiodegradable,thuseﬀectingitsgradualremoval
from the body in the form of fragments qualifying
for excretion through the body’s normal waste re-
moval systems. This process is crucial because high
molecular-mass carriers are not readily eliminated
from the body and in the longer term may cause ad-
ditional toxicity.Eberhard W. Neuse 5
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Scheme 1: Pharmacokinetic in vivo pathway of polymer-drug conjugate.
Ageneralﬂowchartdepictingthepharmacokineticpath-
way of a carrier-anchored antineoplastic agent constructed
in conformance with the aforementioned speciﬁcations is
schematically reproduced in Scheme 1. Most of the earlier
papers in the ﬁeld were concerned with natural macro-
molecules as carriers, such as carbohydrates or proteina-
ceous compounds; yet, as pointed out before, immunogenic-
ity and backbone toxicity, premature biodegradation (alter-
natively, strong resistance to biodegradability), poor stability
in the solid state, and other detrimental features are militat-
ing against major developments on that front. More recently,
in line with the pharmaceutical guidelines discussed further
above in this section, synthetic polymers have taken the lead
in drug conjugation studies for reasons of synthetic versa-
tility and reproducibility, improved control of physical and
chemical behavior patterns, as well as minimization of sys-
temic toxicity and immunogenic properties. Parenthetically
(no metal-based constituents being involved here) we wish
to introduce the reader to a related, rapidly growing branch
of drug conjugation science known as gene therapy. In this
therapeutic modality, synthetic polymers are used in place
of viral vectors as vehicles for the in vivo transport of spe-
ciﬁc nucleic acid agents for the therapeutic manipulation of
pivotal genes involved in malignancies and other diseases.
Despite existing pharmacological shortcomings, gene ther-
apy is bound to take its well-deserved place in forth-coming
therapeutic technology developments [5, 6]. The immensely
wide-ranging drug conjugation topic has been amply sur-
veyed over the years in the literature, and some of the most
outstanding reviews both of yesteryear [7, 8] and up-to-date
[9–14], are recommended to the reader for in-depth study-
ing.
Having thoroughly digested the fundamental principles
of polymer-drug conjugation and the signiﬁcant pharmaco-
logicalbeneﬁtstobederivedfromthismodeofdrugdelivery,
we are ready now for a lecture on the practicalities. Out of a
large number of variously structured carrier types developed
over the past decade, Section 3 will introduce just three types
that have proved to be the predominant role players in the
drug conjugation domain, and their structural peculiarities
willbehighlightedasahelpfulprerequisiteforthediscussion
of the drug anchoring strategies covered in Section 4.
3. THE LEADING CARRIER SYSTEMS
The design and construction of a drug carrier represents a
pivotaltaskinpolymer-drugconjugationasboththeanchor-
ingchemistryandthetherapeuticactivityofthederivedcon-
jugate depend critically on the carrier’s solubility behavior
and resulting “staying power” in solution upon drug con-
jugation. Steric accessibility and reactivity of the anchor-
ing sites additionally contribute to the carrier’s functional
eﬃcacy. A nontoxic chain construction amenable to slow
biodegradation in the spent state (i.e., upon drug liberation)
is a further requirement for optimal eﬃcaciousness. Lastly,
high main-chain ﬂexibility depending on freely rotating sin-
gle bonds in the backbone and the absence of aromatic or
heteroaromatic, sterically blocking units, will be required as
this will increase the entropy of solution, thus reinforcing
the aforementioned staying power of the assembly in solu-
tion. In the following text we will ﬁnd out if, and to what
extent, these prerequisites are met in the structural compo-
sitions of the three selected carrier types: (1) the α,β-DL-
polyaspartamides, (2) the poly(amidoamines), and (3) the6 Metal-Based Drugs
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Scheme 2: Synthesis of polysuccinimide from aspartic acid.
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Figure 4: Copolyaspartamide equipped with solubilizing, target-
directing, and drug-binding moieties.
2-hydroxypropyl-methacrylate polymers (HPMA). In addi-
tion, polyamides obtained by polycondensation processes
will cursorily be discussed because of their sporadic use as
carriers.
3.1. α,β-DL-polyaspartamides
This carrier type has moved into the limelight of polymer re-
searchsomethreedecadesago[15–17].Itisreadilyaccessible
synthetically by high-temperature condensation polymeriza-
tion of DL-aspartic acid in orthophosphoric acid medium,
leading to a polysuccinimide intermediate (see Scheme 2).
In subsequent polymer-homologous reactions conve-
niently performed in a dipolar aprotic solvent such as N,N-
dimethylformamide, the intermediary polysuccinimide is
treated sequentially with two amine nucleophiles (NH2–R1,
NH2–R2; occasionally a third amine, NH2–R3,m a yb ee m -
ployed in this operation), whereby imide ring opening gives
rise to the generation of the ultimate polyaspartamides [18,
19]. These linear polyamides are composed of randomly dis-
tributed aspartamide repeat units bearing N-attached sub-
stituents (R1,R 2, etc.) as introduced by the amine nucle-
ophiles chosen. Scheme 3 depicts this sequence of ring open-
ing steps.
Itshouldbenotedthathereandinsubsequentpolyaspar-
tamide representations, only the α-peptidic forms are shown
for convenience, although the isomeric β-forms, with two
carbon atoms (rather than one only) separating –CO and
NH–, are also present.
Let us now redraw the structural arrangement in
Scheme 3 by substituting a solubilizing entity S for NH–R1,a
homing device H for NH–R2, and a drug-binding functional
group F for NH–R3 (see Figure 4).
It should be evident from the detailed discussion in the
foregoing of structure-function relationships that polyaspar-
tamides complying with this schematic representation will
be able to provide an excellent “workhorse” service in drug
conjugation studies. Speciﬁcally, the following hold. (i) The
vital prerequisite of water solubility will be aﬀorded by the
numerous freely rotating aliphatic main-chain bonds and,
in particular, by the extrachain S units chosen so as to con-
tain tert-amine, hydroxyl, or, perhaps, oligo(ethylene oxide)
groups [20]. These functionalities will be prone to aqua-
tion, that is,hydrogen bond formation with the aqueous sol-
vent, and/or protonation with generation of cationic sites.
(ii) Steric accessibility of the anchoring site F is optimized by
insertion of a suitably long (say, 8–10 atomic constituents)
aliphatic spacer link between F and backbone, thus reducing
any steric hindrance potentially provided by the main chain
proper. (iii) The chain construction has been rendered non-
toxic through use of aspartic acid as the principal molecular
backbone source. (iv) The chain is biodegradable hydrolyti-
cally at the CO–NH links for catabolic fragment elimination
through the globular system of the kidneys upon drug re-
lease, a vital detoxiﬁcation process in light of the fact that,
as mentioned before, large nondegradable macromolecules,
such as vinyl-type polymers and other carbochain macro-
molecules, strongly resist excretion and tend to induce toxic-
ity. Such backbone degradation must be slow and controlled,
however, so as to ensure stability during serum exposure,
yet fragmentation in the endosomal compartment. (see also
remarks in Section 2.2). In the polyaspartamide structure,
these conditions are ideally met: in the serum environment
(pH∼7.5) only minimal hydrolytic CO–NH bond ﬁssion is
observed,whereasintheendosomalspace(pH∼5)suchfrag-
mentation proceeds as expected, albeit slowly. Superimposed
on hydrolytic bond ﬁssion is the process of enzymatic bond
braking, eﬀective both at main-chain NHCO sites and, to a
variable extent, also at drug-binding links. Whereas natural
polypeptides are prone to rapid degradation (unzipping)a s
a consequence of α-peptidase activity in the serum, such un-
zipping isgrosslyimpededbythepresenceofD-conﬁgurated
CH groups and β-peptide units in the chain that are inert to
α-peptidase attack [21]. Section 4 will show how proper use
can be made of these structural features.
3.2. Polyamidoamines
Pioneered in Ferruti’s laboratory [22, 23], these macro-
molecules have proved as versatile as the polyaspartamides,
allowing for the construction of a multitude of unique
carrier compositions. In the simplest mode of synthe-
sis, a monomer equipped with two activated vinyl groups
as in a bis(acryloylamido) compound exempliﬁed by
methylenebisacrylamide or bisacryloylpiperazine, is allowed
to undergo aqueous-phase Michael addition polymerization
withacomonomerthateithercontainstwosecondaryamino
groups for single substitution on each N (see Scheme 4(a))
or else features a primary amine (see Scheme 4(a)), the lat-
ter now being doubly N-substituted in the process. The re-
actions are preferably conducted in aqueous solution and
give rise to polymer structures comprising both amide and
amine functionalities. In the author’s laboratory these stud-
ies were extended to include comonomers featuring two
primary amino groups that are allowed to enter polymer-
ization by single-step Michael addition at each –NH2 un-
der modiﬁed, carefully controlled conditions. This will pro-
duce polyamidoamines possessing secondary amino groups
in the main chain (see Scheme 4(c)), which, in turn, are des-
tined for drug binding [24]. With R2 standing for an ethy-
lene residue, the resulting polymer possesses an intrachainEberhard W. Neuse 7
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Scheme 3: Aminolytic ring opening in polysuccinimide.
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Scheme 4: Diﬀerent modes of Michael addition polymerization of a bisacrylamide.
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Scheme 5: Michael addition polymerization involving mono-N-protected diamine.
–NH–(CH2)2–NH segment important for cis-N,N chelation
of platinum, as will be shown in Section 4.
A special case of sequence (b) in Scheme 4, in which a
mono-N-protected diamine takes the place of H2N–F3,l e a d s
to a polymer possessing the mono-N-protected moiety as
a side group. This strategy thus compels primary diamine
monomers to be incorporated through just one amine func-
tionality instead of two as in (c). Subsequent N-deprotection8 Metal-Based Drugs
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Scheme 6: Synthesis of methacrylamide polymers.
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Scheme 7: Drug conjugation with HPMA copolymer.
then provides a polymer featuring a free –NH2 side-chain
terminaldirectlyavailablefordruganchoring[25].Scheme 5
depicts this reaction course (n = 3–21).
It is obvious from these described synthetic strategies
that the resultant polyamidoamines in all cases are linear
and follow the established rules of construction, in so far
as one may vary the intrachain-type segments as well as—
more usefully—the extrachain-type side groups, in an eﬀort
to provide the vital functions of solubility, target homing,
and drug conjugation. In Section 4 we will learn more about
the versatile use of the amidoamine polymers.
3.3. N-(2-hydroxypropyl)methacrylamides(HPMA)
T h eH P M Ap o l y m e r sh a v ef o l l o w e dag l o r i o u sd e v e l o p m e n t
path since early beginnings in 1970s [26]. On the strength
of preceding methacrylate polymer research in numerous
laboratories, this polymer class, developed almost singularly
in the collaborating laboratories of Kopeˇ cek (synthesis) and
Duncan (biomedical evaluation), has by now most success-
fully entered the forum of global research in polymer thera-
peutics [27–29].
The synthetic approach, illustrated in Scheme 6,i n v o l v e s
the free-radical copolymerization of two or more methacry-
lamide monomers bearing substituents S for provision of
water solubility (almost always a 2-hydroxypropyl moiety),
other substituents, F, for drug anchoring reactions, and still
other functionalities, H, as required for speciﬁc purposes
serving facilitated cell entry, homing to the cancerous target
t i s s u e ,o ri nv i v od e t e c t i o na n dt r a c i n g .
The polymers are thus characterized by a carbochain-
type backbone composed of substituted 1,2-propylene re-
peat units, and these are randomly distributed along the
main chain. In contrast to the polyaspartamide situation,
all basic functionalities are generally preintroduced into
the monomers and are automatically polymer-incorporated
as the free-radical propagation proceeds. In order to fa-
cilitate the drug conjugation step, the respective precur-
sor monomers are methacrylamides substituted with a
spacer-separated para-nitrophenolate group, the latter act-
ing as a convenient leaving group in the ultimate addition-
elimination step leading to the introduction of amine-
functionalized drug species with loss of para-nitrophenol. A
nitrophenolate-terminated repeat unit and its reaction prod-
uct, the drug-conjugate unit, are shown in Scheme 7.
Selected HPMA conjugates derived from the here-
described carriers will be dealt with in Section 4.
3.4. Polyamidespreparedby
polycondensationreactions
Although of less importance, polycondensation products re-
sulting from interfacial or high-temperature condensation
reactions should be included here because monomer varia-
tion results in a variety of carrier structures featuring intro-
duction of –NH− groups useful for drug conjugation. Typ-
ically, exempliﬁed in Scheme 8, a diacid chloride, such as
succinyl chloride, is allowed to react interfacially with a di-
amine like 1,2-bis(3-aminopropylamino)ethane or the sol-
ubilizing commercial Jeﬀ ED-600 (an oligo(ethylene oxide)
terminated at both ends with a primary amino group) [30].
High-temperature solution polymerization in polyphospho-
ric acid provides analogous polyamides, if free diacids are
employed in place of the acid chlorides [31]. The –NH–
(CH2)2–NH– segments in these structures have conveniently
been introduced for platinum chelation as pointed out be-
fore.
4. SELECTED CARRIER-BOUND DRUG MODELS
Having acquired by now the requisite conceptual tools,
we are duly prepared for the ultimate topic: the strate-
gies required to put the carrier-drug assembly together
along biomedically prescribed routes. As we delineate the
scope of this eﬀort in the forth-coming discussions, we
are guided by the requirement to conﬁne the treatment
to metal-based polymer systems and, there again, to those
systems with a medicinal, speciﬁcally therapeutic applica-
tion potential. Among the considerable number of metal-
containing macromolecules that have attracted the biosci-
entists’ interest, we will uniquely focus our attention to the
two most actively researched classes: the metal-coordination
polymer class belonging to the platinum drug family, and
the organometallic class of ferrocene-type iron-containing
conjugates. Both classes, as we will see, turn out to be just
the right types of “guinea pig” as we set out to explore the
broad ﬁeld of medicinal agents conjugated to macromolec-
ular adjuvants. In addition (you guessed it!), it so happens
that it is the development of these two classes to which theEberhard W. Neuse 9
2x ClCO
COCl
+ xH2N NH NH NH2 + xH2N O O
10 2
O NH2
H2O,CH2Cl2,CHCl3;OH −; <0◦C
CO CONH NH NH NH
x
CO CONH O O
10 2
O NH
x
Scheme 8: Synthesis of polyamides by interfacial polymerization.
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Figure 5: Leading platinum drugs in clinical use.
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Scheme 9: Polycondensation of diamines with the tetrachloroplati-
nate dianion.
author’s group has been particularly devoted over the past
four decades. Other metals, such as titanium or ruthenium,
continue to play a role in the ﬁeld marginal enough as yet to
permit us to ignore them within the scope of this text.
4.1. Polymer-platinumconjugates
As metal-based medicinal agents found their way into the
oncologist’s arsenal of antitumor drugs, several decades ago,
platinum containing compounds immediately moved to the
forefront with the advent of the prototype, cisplatin (cis-
diamminedichloroplatinum(II)), and its second-generation
cousins, carboplatin and oxaliplatin (see Figure 5).
Their general mechanism of action involves the forma-
tion of aquated species upon parenteral administration and
subsequent intra- and interstrand crosslinking with intra-
cellular DNA, leading to irreversible lesions in the double-
helix and ultimate cell death. The compounds are highly po-
tent against numerous malignancies per se and in combina-
tion with other antitumor drugs. Set against these highly ac-
claimed performance criteria, the platinum compounds, just
like the metal-free drugs, suﬀer from severe pharmacologi-
cal shortcomings, curtailing clinical eﬀectiveness. Thus, res-
idence times in central circulation are generally short, and
this is paired with rapid excretion through the urinary tracts
and consequent unpredictable variation of drug concentra-
tion. Drug action is nonselective, normal and transformed
cells being equally aﬀected; this leads to signiﬁcant, dose-
limiting acute and chronic toxicities, and in consequence,
therapy discontinuation will frequently be required long be-
fore regression-free cure rates are attained. Lastly, and most
importantly, various forms of drug resistance tend to build
up in the cancerous tissue, which, again, requires treatment
termination. In view of these serious deﬁciencies, active re-
search worldwide has been focused on structural modiﬁca-
tions designed to enhance the overall performance proﬁle
[32–35]. The polymer-drug conjugation modality is playing
an outstanding part in these research endeavors, and, as we
will see in the following section, encouraging progress has
beenmadeuntilnow.Beforegoingintodetails,letusremem-
ber that the present treatise, far from presenting a compre-
hensive review, is intended, ﬁrst and foremost, to provide a
didactic lecture on the topic; hence, it will cover only a small
number of exemplifying conjugate types selected to mirror
general trends in this rapidly expanding ﬁeld of pharmaceu-
tics.Forthestudentwishingto“digdeeper”,Carraher’sexcel-
lent review chapter with original literature quotes is strongly
recommended [36].
4.1.1. Metalcoordinationinvolvingcarrier-bound
nitrogendonorligands
Bystrictdeﬁnitionofthepolymer-drugconjugationconcept,
the presynthesis of a suitable carrier polymer of biomedically
“approved” structure is followed in another reaction step by
the bioreversible attachment of the drug. Before we study the
exemplifying macromolecules compliant with this deﬁnition
of drug conjugation, it is only fair to Charles Carraher, the
pioneering scientist, that we are acquainted ﬁrst with a sepa-
rate synthetic approach deviating from that routine, yet sig-
niﬁcant in its own right because it is one of the earliest major
assaultsontheproblemofprovidingbiomedicallyimportant
metal compounds in polymeric form. This approach, devel-
oped in meticulous detail in Carraher’s laboratory, embodies10 Metal-Based Drugs
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Scheme 10: Platination of amine-functionalized carriers.
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Scheme 11: Platinum atom coordinated by intrachain ethylenediamine segment.
the aqueous-phase polycondensation of the tetrachloroplati-
nate(II) dianion with diamines, giving polymers with the
metalcoordinateddirectlyintothemainchainincis-diamine
fashion, as shown in Scheme 9. The link R in this process
stands for a variety of aliphatic, aromatic, and heteroaro-
matic units, or simply for a direct bond, and molecular
masses attain the 106 Dalton level. Biological test data, no-
tably for antiviral and antiproliferative performance against
a number of cancer cells, at that time demonstrated a “leap
forward” in platinum-drug cancer therapy.
This brings us to the main stream of drug conjugate
development: the polymerhomologous drug anchoring to
presynthesized carrier polymers. In this principal mode,
polymer attachment of the square-planar structural element
of cisplatin can be achieved via several reaction paths, in the
design of which care must be taken to include suitable cleav-
age sites in the assembly for in vivo liberation of the bioactive
agent from the carrier vehicle. In principle, two approaches
of metal-binding are available. In the ﬁrst, the metal center
is bound via amine ligands attached to the carrier. In the
second mode, the metal is polymer-bound via the leaving
group ligands. In the ﬁrst case, the result will be a structure
comprising a Pt center tightly bound to the carrier, and re-
lease of the active complex will require cleavage of a suit-
able anchoring segment in the side chain. This is a time-
dependentprocess,andtheconjugatessoconstructedshould
prove most eﬃcacious in long-term administration. In the
secondcase,theactivecomplexisreleasedfromtheconjugate
through (generally hydrolytic) cleavage of the bonds con-
necting the metal with the leaving groups, resulting in aqua-
tion. Releaserateswillbehigherin thismodel, whichshould,
hence, ﬁnd optimal utilization in short-term administration,Eberhard W. Neuse 11
CO NH
CONH
NMe2
3x
CO NH
CONH
NH
NH2
x
PtCl4
2−,H 2O
−HCl; 25–50◦C
CO NH
CONH
NMe2
3x
CO NH
CONH
HN
H2N
Pt
Cl
Cl
x
Diamine coordination
(a)
CO NH
CONH
NMe2
4x
CO NH
CONH
NH2
x
PtCl4
2−,H 2O
−HCl; 25–50◦C
CO NH
CONH
NMe2
4x
CO NH
CONH
NH2
OH2
Pt
Cl
Cl
x
Monoamine coordination
(b)
Scheme 12: Platinum conjugation through carrier-attached amine donors.
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Scheme 13: Platinum chelation patterns.
whenever a boost is required for rapid eﬀects. Let us look at
the ﬁrst case: conjugation via carrier-bound amine ligands
(see Scheme 10).
In the simplest fashion (type A, with R = CH2CH2−), the
>PtCl2 moiety is incorporated into a carrier structure con-
taining ethylenediamine as a main-chain segment. Such car-
riers may be prepared by Michael addition polymerization
with selected tetramine comonomers, and Scheme 11 pro-
vides an illustrating example. A related metal bonding pat-
tern exists in certain polyethyleneimines prepared by Carra-
her’s group. In conjugates of these structures the cis-diamine
ligand system is strain-free and thus smoothly generated.
Platination of carriers of type B (see Scheme 10)l e a d st o
conjugates in which the entire cisplatin skeleton is located
outside the main chain. With R standing for a direct bond
or, less favorably, no more than a single atomic constituent,
metal coordination through chelation with both amino
groups would appear to be sterically feasible. Exemplifying
product structures have indeed been obtained in Carraher’s
laboratory [36] by platination of a vinylamine/vinylsulfonate
copolymer and of the natural (and hence, biodegradable)
polymer chitosan. A special case of type B has been reported
by Howell and Walles [37]. These authors inter alia presyn-
thesized a cisplatinanalogwithboth NH3 ligandsreplacedby12 Metal-Based Drugs
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Figure 6: Platinum conjugation through repeat units featuring carrier-attached N- and O-donors.
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Figure 7: Examples of O,O-coordinated platinum in close main-chain proximity.
the two NH2 groups in 1,2-diamino-4-hydroxybenzene. This
reactant was then allowed to bind to poly(vinylpyrrolidone)
by molecular complexation, that is, in a form permitting its
release from the carrier by simple dissociation [37].
Appreciably more research has been performed with
conjugates falling into the pattern of types C and D (see
Scheme 10). In the author’s laboratory, polyaspartamides
prepared per Scheme 3 (yet including only two R-substituted
units) were converted to platinated species by treatment
with tetrachloroplatinate dianion in aqueous phase. The two
platination runs in Scheme 12 exemplify this reaction type.
Whereas the upper reaction leads to a conjugate with cis-
N,N
 -coordinated platinum [38,39],theloweronegivesrise
to the formation of a structure wherein the metal is polymer-
bound through a single N donor ligand [40]. In both cases,
the ﬁrst depicted, potentially cationic repeat unit provides
both solubilizing and homing functions. Cell culture tests
s h o w e db o t hc o n j u g a t et y p e st ob ee q u a l l ya n t i t u m o r - a c t i v e ,
and while with the upper conjugate ranked ﬁrst in a series
of cytotoxicity tests [41], the lower one ranked ﬁrst in an in
vivo toxicological study, demonstrating some 100-fold lower
toxicity than determined for the cisplatin standard [42].
Similar platination patterns were reported from Ruth
Duncan’s proliﬁc laboratory (reviewed [36]), with HPMA
polymers used as the carriers. Broad-based biological inves-
tigations provided excellent results with respect to release
rates, toxicological behavior, and cell-killing properties both
in vitro and in vivo.
Somewhat related to type D is a conjugate synthesized
by Gianasi et al. [43] and further investigated by Howell
[44, 45], in which only one nitrogen donor ligand, in coop-
eration with an oxygen donor, partakes in platinum coordi-
nation (see Figure 6(a)). The compound, an HPMA deriva-
t i v e ,i sn o t e w o r t h ya si tf e a t u r e sa n dN , N , N
 ,O-coordination
square around the Pt atom. The compound underwent in
vitro and Phase I clinical tests with highly promising results,
low toxicities being paired with excellent antiproliferative ac-
tivities [44, 45].
Ad i ﬀerently structured polymer type featuring N,O-
coordination of the metal has just been reported byEberhard W. Neuse 13
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Scheme 14: Synthesis of conjugate featuring extrachain-type 1,2-carboxylatohydroxylato coordination of platinum.
CONH
NH
Spacer
HOOC COOH
Cisplatin, H2O
CONH
NH
Spacer
OOC COO
Pt
H3NN H 3
Scheme 15: HPMA-derived dicarboxylato-coordinated platinum.
Bariyanga [46]. Representative compounds contain the
Fc−CH=N(R)−Pt(Cl2)−O− segment (Fc = ferrocenyl) con-
nected to a poly(ethylene oxide) terminal (see Figure 6(b)).
These polymers are thus characterized by the presence of
both a ferrocene and a platinum complex. While no biomed-
ical test data are available, it would be interesting to ﬁnd out
in future studies whether such compounds display coopera-
tive cytotoxicity between the two drug species.
4.1.2. Metalcoordinationthroughcarrier-boundoxygen
donorligands
In the polymer described in this section the Pt complex is
conjugated through two oxygen donor ligands provided by
the carrier. Contrasting with those covered in the preced-
ing section, these conjugates follow a release mechanism in-
volving hydrolytic Pt bond cleavage, thus requiring no spe-
cial bioﬁssionable links in the carrier for drug liberation. In
structures of this kind, the anchoring mechanism must be
designed with a view to counteracting the inherently lim-
ited stability of the O−Pt bond. The preferred approach
to this goal involves the construction of 5–7-membered
chelate rings connecting the metal atom with the carrier-
attached donor ligands. Scheme 13 oﬀers acceptable choices,
for which the literature provides exemplifying experiments
(reviewed by Carraher [36] ) ;w h e r e a st y p e sAa n dDe x -
emplify carrier binding through directly backbone-attached
hydroxylato- or carboxylato-type oxygen donors, the types
B, C, and E represent structures with spacers interposed be-
t w e e nc a rri e rb a c k b o n ea n do x y g e nd o n o r .F u rt h e rw o r kwi l l
determine the extent to which biological performancewill be
aﬀected by the coordinating atoms’ special remoteness from
the main chain.
Figure 7 provides an example each of type A- and type
D-derived conjugates without further comments on the syn-
thetic methodology [47].
Considering now the B- and C-type platination re-
actions of Scheme 13, the literature provides numerous
reaction sequences originating from uniquely function-
alized carriers. Scheme 14 represents a prototype reac-
tion starting out from polysuccinimide [47]. In all these
exemplifying cases, the platination agent has been trans-1,2-
diaminocyclohexanediaquaplatinum(II) dinitrate (DACH-
Pt), a reactant preferred by us and others over the tetra-
chloroplatinate dianion on grounds of favorable biological
behavior, notably the lack of crossresistance with cisplatin.
We will now focus our attention to the bonding pat-
tern of type E (see Scheme 13) which underlies the largest
body of recent carrier-Pt conjugation research. Thus, Ohya
et al. [48] prepared a water-soluble poly(ethylene oxide)
carrying a methoxy terminal and, at the other end, a
propylmalonate moiety suitable for platination with hy-
drolyzed cisplatin. The release behavior was examined and14 Metal-Based Drugs
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the cytoxicity against lymphocytic leukemia cells was deter-
mined. Good activity, although slightly below that of cis-
platin, was observed. A study by the afore-mentioned group
of Duncan et al. produced numerous dicarboxylatoplatinum
compounds, among others, HPMA-derived conjugates pos-
sessing carrier-attached dicarboxylato ligands [43]. Upon
treatment with hydrated cisplatin, these converted to highly
bioactive cis-dicarboxylato-chelated platinum polymers as
exempliﬁed in Scheme 15 for the aﬀected repeat unit.
A recent patent, outstanding among the many studies
of polymeric phosphazene drugs [49], describes polyphos-
phazene derivatives of dicarboxylato-coordinated platinum
with activity inter alia against the gastric tumor YCC-3 [50].
A simpliﬁed repeat unit structure is reproduced in Figure 8.
Numerous conjugates of type E have in recent years been
synthesized in the author’s laboratory, of which only a sin-
gle example is reproduced in Scheme 16. The carrier educt
in this reaction is a polyamidoamine equipped with a solu-
bilizing N,Ndimethylaminopropyl side chain and an aspar-
tic acid-derived dicarboxylate, and platination once more in-
volves treatment with DACH-Pt [47, 51]. This polymer and
related structures have shown outstanding antiproliferative
performance, on the strength of which, a major development
program has been initiated.
This section would be incomplete without a brief treat-
ment of the comprehensive research eﬀorts by the group
of Bilha Schechter and collaborators. These workers at the
Weizmann Institute of Science have been involved for some
decades now in studies aiming at the provision of platinum-
containing polymers antibody-modiﬁed for immunotarget-
ing to human tumors. Representative compounds are a
polyglutamic acid providing chelating capacity of type E (see
Scheme 13) and some carboxymethyl derivatives of dextran
with similar, albeit less structurally deﬁned metal coordina-
tion patterns. Excellent biomedical test results on a broad
front attest to the soundness of the development program
in Schechter’s highly productive laboratory. For in-depth
reviews of the Weizmann group’s activities, see Siegmann-
Louda and Carraher [36], and Chen et al. [52].
4.2. Polymer-ferroceneconjugates
Contrasting with the platinum drugs, which have ﬁrmly
established their prominent position as antitumor agents
in clinical use, research in the realm of ferrocene-based
chemotherapy is still at an experimental stage. However,
biomedical test data, preliminary as they are, have shown
overwhelming promise, stimulating comprehensive investi-
gations currently in progress worldwide. The core organo-
iron compound, di-(η5-cyclopentadienyl)iron(II), has been
under scientiﬁc and technical scrutiny for more than half a
century,andnumeroustopicalsurveys,includingfundamen-
tal physical and chemical applications, have appeared in the
literature (surveyed in two books [53, 54]). The fascinatingEberhard W. Neuse 15
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ferrocene chemistry, pivotally involving the compound’s re-
dox equilibrium with its one-electron oxidation product, the
ferricenium cation, has prompted wide-ranging investiga-
tions of this electrochemical ferrocene/ferricenium couple in
the biological environment, with ultimate ramiﬁcation into
the topic of carrier-bound ferrocene conjugates.
Thebulkofcontributionstotheseresearchdevelopments
has materialized in the author’s laboratory, as attested by
more than 50 pertinent papers published by our group until
n o w .T h er e a d e ri sr e f e rr e dt os o m er evi e w s[ 54–57] covering
this prominent development trend.
Let us look now in detail at the large family of polymer-
bound ferrocenes designed for biomedical applications. As
we embark on this theme, we realize that, in the “old days”
of ferrocene polymer development spanning the 1950–1970
decades, macromolecular ferrocenes and other metallocenes16 Metal-Based Drugs
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Scheme 21: Ferrocenylation of polyaspartamide featuring extrachain-type hydroxyl groups; R = aliphatic segment.
hadbeensynthesizedinhugenumbers(reviewedinthebook
[54] and three book chapters [58–60]), yet most of those
were hydrophobic and lacked hydrosolubility and, hence,
were not considered in later work. An entirely new concept
had to be developed for the purpose of rendering any metal-
locene polymers qualiﬁed for biological examinations. That
concept, as we learned in Section 2, originated a decade later.
It embodies the technique of conjugation so successfully uti-
lized in the design of polymeric platinum and other drugs,
and in the present section it will be seen to be instrumental
in the synthesis of carrier-bound ferrocene compounds.
Earlier exploratory studies [61] demonstrated the fea-
sibility of carrier binding and provided a range of var-
iously structured conjugates meeting the crucial require-
ment of water solubility. Ferrocenylamines, initial candidate
agents for ferrocenylation because of their strongly nucle-
ophilic functionality, were soon omitted on electrochemi-
cal grounds. Ferrocenyl-carboxylic acids, on the other hand,
notably 4-ferrocenylbutanoic acid, emerged in those earlier
investigations as suitably functioning compounds provid-
ing electrochemically stable ferricenium counterparts [62–
64]. The butanoic acid derivative soon became the ferro-
cenylation agent of choice in all subsequent conjugation
developments in preference over other chemically feasible
coupling mechanisms. Again, the polyaspartamides intro-
duced in Section 3.1 turned out to be the most versatile
and functional carriers; equipped with NH2-terminated side
chains, they soon became, and still are, the “workhorse”
carrier polymers in our laboratory, conveniently undergo-
ing coupling reactions in aprotic medium with the ferro-
cenyl acid via carboxyl group activation, or directly with
the aid of strong coupling agents, such as HBTU (O-[1H-
benzotriazol-1-yl]-1, 1,3,3-tetramethyluronium hexaﬂuo-
rophosphate).Scheme 18showsatypicalreactionstepofthis
type, singled out here on account of the conjugate’s partic-
ularly rewarding cytotoxic behavior; in vitro screens against
the HeLa human cervix epithelial cancer revealed a cell-
killing activity (on metal-to-metal equivalent basis) twice
that of the cisplatin standard, and a fourfold superiority over
cisplatin against Colo 320DM, a notoriously drug-resistant
human colon cancer line [65]. Interestingly, similar conju-
gates possessing nonbasic hydroxyalkyl side groups in place
of the strongly basic tert-amine-terminated solubilizing and
homing moiety of the drawn structure gave rather poor re-
sults, reﬂecting the lowered aﬃnity to the cancerous cell (see
Section 2.2) because of lacking basicity.
Amongthegreatvarietyofothercarriertypes,wecitethe
primary amine-functionalized amidoamine polymer synthe-
sized by Michael polyaddition (see Section 3.2); readily fer-
rocenylated with HBTU mediation [66], it converts to a con-
jugate featuring a long (8 atomic constituents) spacer con-
necting the metallocene to the main chain as depicted in
Scheme 19.
On the other hand, a related amidoamine-type carrier
characterizedbyanadditionalintrachain−NH−NH−group
yet lacking the NH2-spacer side chain converts to a conjugate
bydirectN-acylationofthemainchain[67](seeScheme 20).
Subjected to the same cell culture tests as cited above, this
ferrocene-loaded polymer, again, performed distinctly better
than the cisplatin standard.
Lastly, we mention an anchoring step involving O-acyl-
ation. To this end, various hydroxyalkyl-substituted poly-
aspartamides were treated in aprotic medium with ferro-
cenylbutanoic acid in the presence of N,N
 -dicyclohexyl-
carbodiimide coupling agent and 4-(dimethylamino)pyr-
idine (DMAP) catalyst [68]. Scheme 21 shows a representa-
tive run, with x/y varying from about 3 to 10 as a function of
molar reactant ratios.
A conjugate of this type, with x/y = 2.6, subjected to
an in vivo toxicity test, gave a maximum tolerated dose ofEberhard W. Neuse 17
0.43mmol Fe/kg, more than 20-times higher than deter-
mined for the cisplatin standard [69]. The polymer is thus
some 20-fold less toxic than the standard, and compara-
ble toxicity behavior is also displayed by selected amide-
linked analogs. These ﬁndings, in conjunction with cell-
killing properties, augur exceptionally well for the class of
ferroceneconjugatesascancer-chemotherapeuticagents,and
their future looks highly promising indeed.
5. SUMMARY AND CONCLUSIONS
Mankind,alongitsarduousdevelopmentpathfromearlyho-
minidsviaHomoerectustothepresent“status”ofHomosapi-
ens, has never been spared the experience of bodily injuries
and the suﬀering from debilitating or even lethal diseases.
Yet the human spirit has at all times searched for therapeutic
weapons to overcome, or at least deter, those inimical adver-
saries. Even at the sophisticated level of human enterprise at-
tained by now, we have come to accept the limited eﬃcacy of
those therapeutic weapons against many serious inﬁrmities
and the pressing need for continued forceful research activi-
tiestoeliminateexistingthreatstoourwell-being.Cancerous
diseases stand out amid those threats as particularly dreaded
adversaries, and on these we have focused our attention in
the present discourse.
We have acquainted ourselves with the cancer problem
per se, with the current chemotherapeutic treatment limi-
tations, and, getting into the core topic, with the promis-
ing and highly challenging present research endeavors in the
ﬁeld of polymer-drug conjugation. In doing so, we have fol-
lowed the development of one of the leading polymer-based
chemotherapeutic tools in the ﬁght against cancer, with em-
phasis on platinum- and iron-based drug systems. We have
found out that the expediency of using goal-designed, water-
soluble, and biologically acceptable macromolecules as tem-
porary transport vehicles for powerful, yet potentially toxic,
andresistance-promotingmedicinalagentshas,beyondearly
doubts and objections, matured to a practicable technology.
It is to be hoped that the facts and arguments here-presented
will encourage many students of the biochemical and phar-
maceutical sciences to participate in the global eﬀorts to pro-
mote and reﬁne the drug conjugation modality for the fu-
ture beneﬁt of the victims of neoplastic and other diseases
Scheme 17.
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